Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Regulatory Routine +

MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

By The Northwire Desk — AI Analysis May 25, 2026 · 07:00 MGRO · 0.57 MustGrow Biologics Corp.
Executive Summary
  • MustGrow Biologics Corp. received registration approvals for its TerraSante(TM) organic biofertility product from Texas, Utah, and Montana agriculture departments on May 25, 2026.
  • This expansion adds three new states to an existing regulatory footprint that includes California, Florida, Georgia, Arizona, Idaho, Oregon, and Washington.
  • The product is a mustard-derived, organic wettable powder designed to enhance soil microbiome health, nutrient/water use efficiency, and crop yields.
  • Texas market context highlights significant value in melons ($108 million), potatoes ($104 million), pecans ($85 million), and grapefruits ($59 million).
  • The company previously announced Georgia registration on April 28, 2026, indicating a steady progression of US regulatory approvals.
Material Impact
  • Incremental Market Access: The approval in Texas is significant due to the high value of crops (melons/potatoes), but it follows logically from previous approvals (Georgia) and management's stated strategy to expand US sales. It does not represent a sudden, unexpected shift in business model.
  • Revenue Catalyst: These registrations enable immediate sales in new territories, supporting the revenue growth trajectory seen in 2025 ($8.3M vs $0.4M). However, monetization takes time as farmers adopt products for the next growing season.
  • Cash Flow Implications: While positive for top-line growth, this news does not immediately resolve the company's liquidity position. The company reported a net loss of $7.3 million in 2025 with only $0.9 million cash on hand at year-end (raised $2M in Jan 2026).
  • Expectation Alignment: Management previously indicated progress on registrations and manufacturing scale-up in their December 2025 letter to shareholders. This news confirms execution of that plan rather than introducing new strategic pivots.
  • Risk Mitigation: Expanding the addressable market helps justify the inventory buildup ($2.0M) but does not guarantee immediate cash conversion to cover operating losses.
MGRO · Price
Company Overview
  • Company: MustGrow Biologics Corp., focused on organic biofertilizers and biopesticides derived from mustard seed meal.
  • Flagship Product (TerraSante): Organic wettable powder biofertility product targeting soil microbiome health and crop yields. Registered in multiple US states including CA, FL, GA, TX, UT, MT.
  • Secondary Product (TerraMG): Biopesticide for clubroot disease suppression in canola; field trials showed up to 95% reduction in spores and yield increases of 7 bushels/acre.
  • Distribution: Previously operated NexusBioAg Canadian distribution division (closed April 2026) to focus resources on US TerraSante sales.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 26, 2026 · 17:01

MustGrow Biologics Corp. Announces Results of Shareholder Meeting

Management Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other